Celecoxib in the treatment of primary dysmenorrhea: Results from two randomized, double-blind, active- and placebo-controlled, crossover studies

Clinical Therapeutics

Volumn 31, Issue 6, 2009, Pages 1192-1208

  Daniels, Stephen ^a   Robbins, Jeffery ^b   West, Christine R ^b   Nemeth, Mary Anne ^b  

^a Premier Research   (United States)

^b PFIZER INC   (United States)

Author keywords

celecoxib; efficacy; naproxen sodium; primary dysmenorrhea; tolerability

Indexed keywords

ANALGESIC AGENT; CELECOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ADULT; ANALGESIA; ARTICLE; BREAST TENDERNESS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; LABORATORY TEST; LIVER TOXICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENTAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN APPENDAGE DISEASE; SKIN TOXICITY; SWEATING; TACHYCARDIA; THROMBOCYTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VITAL SIGN;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DYSMENORRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; NAPROXEN; PAIN MEASUREMENT; PYRAZOLES; SULFONAMIDES; YOUNG ADULT;

EID: 68649111661     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.003     Document Type: Article

References (51)

1. Wolf L.L., and Schumann L. Dysmenorrhea. J Am Acad Nurse Pract. 11 (1999) 125-130 quiz
2. Wolf L.L., and Schumann L. Dysmenorrhea. J Am Acad Nurse Pract. 11 (1999) 131-133
3. Coco A.S. Primary dysmenorrhea. Am Fam Physician. 60 (1999) 489-496
4. Dawood M.Y. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 84 (1988) 23-29
5. French L. Dysmenorrhea. Am Fam Physician. 71 (2005) 285-291
6. Nasir L., and Bope E.T. Management of pelvic pain from dysmenorrhea or endometriosis. J Am Board Fam Pract. 17 Suppl (2004) S43-S47
7. Rosenwaks Z., and Seegar-Jones G. Menstrual pain: Its origin and pathogenesis. J Reprod Med. 25 Suppl (1980) 207-212
8. Morrison B.W., Daniels S.E., Kotey P., et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol. 94 (1999) 504-508
9. Chan W.Y., and Dawood M.Y. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res. 8 (1980) 1443-1447
10. Hendrix S.L., and Alexander N.J. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception. 66 (2002) 393-399
11. García Rodríguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs [published correction appears in Lancet. 1994;343:1048]. Lancet. 343 (1994) 769-772
12. Singh G., and Rosen Ramey D. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 51 (1998) 8-16
13. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthri-tis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
14. Celebrex (celecoxib) [prescribing information]. http://pfizer.com/files/products/uspi_celebrex.pdf Accessed April 28, 2008
15. Gimbel J.S., Brugger A., Zhao W., et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther. 23 (2001) 228-241
16. Petrella R., Ekman E.F., Schuller R., and Fort J.G. Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: Results of a doubleblind, randomized controlled trial. Clin J Sport Med. 14 (2004) 225-231
17. Bertin P., Béhier J.M., Noël E., and Leroux J.L. Celecoxib is as efficacious as naproxen in the management of acute shoulder pain. J Int Med Res. 31 (2003) 102-112
18. Petri M., Hufman S.L., Waser G., et al. Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis. J Rheumatol. 31 (2004) 1614-1620
19. Ekman E.F., Wahba M., and Ancona F. Analgesic efficacy of perioperative celecoxib in ambulatory arthroscopic knee surgery: A double-blind, placebo-controlled study. Arthroscopy. 22 (2006) 635-642
20. Cheung R.C., Krishnaswami S., and Kowalski K. Analgesic efficacy of celecoxib in postoperative oral surgery pain: A single-dose, two-center, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 29 Suppl (2007) 2498-2510
21. Moore R.A., Derry S., Makinson G.T., and McQuay H.J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports [published correction appears in Arthritis Res Ther. 2006;8:401]. Arthritis Res Ther. 7 (2005) R644-R665
22. Singh G., Fort J.G., Goldstein J.L., et al., the SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study [published correction appears in Am J Med. 2006;119:801]. Am J Med. 119 (2006) 255-266
23. Scheiman J.M. Outcomes studies of the gastrointestinal safety of cyclo-oxygenase-2 inhibitors. Cleve Clin J Med. 69 Suppl 1 (2002) S140-S146
24. World Medical Association Declaration of Helsinki (WMA). Ethical principles for medical research involving human subjects [WMA Web site]. http://www.wma.net/e/policy/b3.htm Accessed November 20, 2008
25. Senn S. Cross-Over Trials in Clinical Research. 2nd ed. (2002), United Kingdom, Chichester 35-85 New York, NY: John Wiley & Sons
26. Miller R.G. Survival Analysis. (1998), United Kingdom: John Wiley & Sons, Somerset 74-75
27. Cox D.R. Regression models and life-tables. J Roy Stat Soc Ser B Metho. 34 (1972) 187-220
28. Burton A.L., Boortz-Marz R.L., and Cabrera J.A. Pre-emptive use of celecoxib in the treatment of primary dysmenorrhea. Reg Anesth Pain Med. 26 Suppl 2 (2001) 108
29. Bitner M., Kattenhorn J., Hatfield C., et al. Efficacy and tolerability of lu-miracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract. 58 (2004) 340-345
30. Malmstrom K., Kotey P., Cichanowitz N., et al. Analgesic efficacy of etoricoxib in primary dysmenorrhea: Results of a randomized, controlled trial. Gynecol Obstet Invest. 56 (2003) 65-69
31. Sahin I., Saraçoglu F., Kurban Y., and Türkkani B. Dysmenorrhea treatment with a single daily dose of rofecoxib. Int J Gynaecol Obstet. 83 (2003) 285-291
32. Daniels S.E., Talwalker S., Torri S., et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol. 100 (2002) 350-358
33. Daniels S.E., Torri S., and Desjardins P.J. Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen. J Gen Intern Med. 20 (2004) 62-67
34. Bresalier R.S., Sandler R.S., Quan H., et al., the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemopre-vention trial [published correction appears in N Engl J Med. 2006;355:221]. N Engl J Med. 352 (2005) 1092-1102
35. US Food and Drug Administration (FDA). Alert for healthcare professionals: Valdecoxib (marketed as Bextra) [FDA Web site]. http://www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.htm Accessed April 28, 2008
36. Solomon S.D., McMurray J.J., Pfeffer M.A., et al., the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 352 (2005) 1071-1080
37. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al., the APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 355 (2006) 873-884
38. Arber N., Eagle C.J., Spicak J., et al., the PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 355 (2006) 885-895
39. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 1 (2006) e33
40. White W.B., West C.R., Borer J.S., et al. Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. Am J Cardiol. 99 (2007) 91-98
41. Hernández-Díaz S., Varas-Lorenzo C., and García Rodríguez L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 98 (2006) 266-274
42. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclo-oxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
43. Ekman E.F., Fiechtner J.J., Levy S., and Fort J.G. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: A multicenter, double-blind, randomized, controlled trial in acute ankle sprain. Am J Orthop. 31 (2002) 445-451
44. Mehlisch D.R., and Fulmer R.I. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Womens Health. 6 (1997) 83-92
45. Mehlisch D.R. Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. Clin Ther. 12 (1990) 398-409
46. Milsom I., Minic M., Dawood M.Y., et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: A pooled analysis of five studies. Clin Ther. 24 (2002) 1384-1400
47. Marjoribanks J., Proctor M.L., and Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev. (2003) CD001751
48. Goldstein J.L., Eisen G.M., Burke T.A., et al. Dyspepsia tolerability from the patients' perspective: A comparison of celecoxib with diclofenac. Aliment Pharmacol Ther. 16 (2002) 819-827
49. Leese P.T., Hubbard R.C., Karim A., et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol. 40 (2000) 124-132
50. Freestone S., and Bello A. Comparison of the effects of celecoxib, meloxicam, and nimesulide on platelet function in healthy subjects. Ann Rheum Dis. 64 Suppl III (2005) 495 Abstract
51. Kouides P.A. Evaluation of abnormal bleeding in women. Curr Hematol Rep. 1 (2002) 11-18